FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to medicine, namely to a liposome composition for application in peritoneal dialysis for patients with from endogenous or exogenous intoxication, wherein the pH inside the liposomes is characterized by the pH in the peritoneal cavity and is preferably 1.5-4.0 or 9.0-10.0, and wherein the pH inside the liposomes results in formation of a charged toxin, incorporated into a liposome.
EFFECT: invention provides detoxification by charged toxin capturing within liposomes.
8 cl, 5 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| STABILIZED PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHECIN | 2016 |
|
RU2732567C2 |
| METHOD OF PRODUCING VESICLES WITH TRANSMEMBRANE GRADIENT pH | 2016 |
|
RU2717824C2 |
| NEW THERMALLY-SENSITIVE LIPOSOMES CONTAINING THERAPEUTIC AGENTS | 2008 |
|
RU2497499C2 |
| HYPER-STABILIZED LIPOSOMES INCREASING DIRECTED TARGETING OF MITOTIC CELLS | 2018 |
|
RU2765736C2 |
| LIPOSOMAL DRUG FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2756755C2 |
| PREORAL DELIVERY SYSTEM FOR PROTEIN SUBSTANCE (OPTIONS), PROTECTIVE COATING FOR DELIVERY SYSTEM (OPTIONS) | 2014 |
|
RU2665367C2 |
| LIPOSOMAL ANTITUMOR COMPOSITIONS | 2017 |
|
RU2756837C2 |
| INJECTABLE DOSAGE FORM OF OLIGOPEPTIDE PREPARATION FOR TREATING MULTIPLE SCLEROSIS AND METHOD FOR PRODUCING IT | 2010 |
|
RU2561582C2 |
| AGENT IMPROVING ANTI-CANCER EFFECT AND CONTAINING LIPOSOMAL AGENT CONTAINING OXALIPLATIN, AND ANTI-CANCER AGENT CONTAINING LIPOSOMAL AGENT | 2009 |
|
RU2492863C2 |
| IMPROVED LIPOSOMES AND THEIR APPLICATION | 2008 |
|
RU2482837C2 |
